Kentaro has been a Corporate Venture Capital Manager at Asahi Kasei since December 2015, focusing on investments in the healthcare industry to nurture new products and services that complement Asahi Kasei’s operations in healthcare which include pharmaceuticals, diagnostics, and medical devices.
His current focus is medical information and communication technologies (ICTs) with respect to remote patient monitoring for chronic diseases (such as chronic heart failure, asthma, and epilepsy).
Kentaro began his career in Asahi Kasei’s pharmaceutical operations in Japan and became an integral part of Asahi Kasei’s pharmaceutical business development activities in China. He later joined Asahi Kasei’s Corporate R&D organization to search for new products and technologies in areas not served by Asahi Kasei’s core healthcare subsidiaries of Asahi Kasei Pharma, Asahi Kasei Medical, and ZOLL Medical. He joined Asahi Kasei Corporation in April 1998. He received a B.A. from Keio University and his MBA from City University London.
Joe joined the CVC team in May 2018. Before joining CVC, he worked in electronics material section as a marketing manager, focusing on South East Asia, India and U.S market. Prior to that, he studied for an MBA at University of Cambridge as well as Human Resource Management and Employment Relations at London School of Economics and Political Science. Prior to the MBA course, he worked in marketing department for metal products with a focus on Oil & Gas industry in China, Europe and U.S.. Before that, he was in charge of marketing and sales for construction material for Japan market. He received an MBA from University of Cambridge, a BA in Law from Waseda University and a BA in Commerce from Nihon University.
Kohei Miyabe has been working for CVC in Asahi Kasei America since April 2018, focusing on life science and advanced materials. Before joining CVC, he worked for R&D in Asahi Kasei Pharma as a formulation scientist for 5 years. He has a master's degree of agricultural science from Nagoya University in Japan.
Dr. Yasutaka Kurishita has been a manager at Asahi Kasei CVC since January 2018, focusing on materials. He joined Asahi Kasei Corporation in April 2014, and worked on R&D of membrane separation at Corporate R&D Center over 4 years. Prior to that, he was a JSPS research fellow at Kyoto University and a visiting scholar at Harvard Medical School,and engaged in research of chemical biology. He received his PhD, MS and BS in synthetic and biological chemistry from Kyoto University.
Founded in 1920s, Asahi Kasei is a diversified business based in Tokyo focused on three primary sectors: Materials, Homes and Healthcare.
Asahi Kasei Corporate Venture Capital was established in 2008 and is focused on investing in innovative global companies in areas of strategic importance to Asahi Kasei. Our primary mission is to create new long-term business opportunities for Asahi Kasei. Our team, based in Menlo Park and the Boston area, consists of senior professionals with backgrounds in R&D, start up operations and venture capital.
Asahi Kasei invests across all stages. Our initial investment size can range from several hundred thousand dollars up to several million, depending on the opportunity. Given the right situation, Asahi Kasei can lead investments.